Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study. (PubMed, J Cutan Med Surg) - Sep 26, 2026 - "Omalizumab is an effective control therapy for CSU in a real-world setting. Abrupt discontinuation leads to rapid relapse in the majority of patients. Gradual dose spacing represents a promising strategy to prolong remission and reduce drug burden, particularly in patients exhibiting excellent initial therapeutic response."
Journal • Retrospective data • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|
|
Astrid Lappi; Federica Sardanelli; François Rosset; Giovanni Cavaliere; Luca Mastorino; Matteo Brizio; Nadia Sciamarrelli; Paolo Borrelli; Pietro Quaglino; Silvia Borriello; Simone Ribero; Sophie Frassy
|